Perceptive Advisors LLC bought a new position in shares of Repligen Co. (NASDAQ:RGEN) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 87,400 shares of the biotechnology company’s stock, valued at approximately $3,349,000. Perceptive Advisors LLC owned approximately 0.20% of Repligen as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in RGEN. Teachers Advisors LLC boosted its holdings in Repligen by 2.4% in the 1st quarter. Teachers Advisors LLC now owns 58,081 shares of the biotechnology company’s stock worth $2,044,000 after acquiring an additional 1,386 shares during the period. Aperio Group LLC boosted its holdings in Repligen by 137.2% in the 2nd quarter. Aperio Group LLC now owns 34,076 shares of the biotechnology company’s stock worth $1,412,000 after acquiring an additional 19,710 shares during the period. US Bancorp DE boosted its holdings in Repligen by 1.2% in the 2nd quarter. US Bancorp DE now owns 4,629 shares of the biotechnology company’s stock worth $191,000 after acquiring an additional 54 shares during the period. Russell Investments Group Ltd. boosted its holdings in Repligen by 45.1% in the 2nd quarter. Russell Investments Group Ltd. now owns 150,701 shares of the biotechnology company’s stock worth $6,245,000 after acquiring an additional 46,815 shares during the period. Finally, Municipal Employees Retirement System of Michigan boosted its holdings in Repligen by 4.7% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,050 shares of the biotechnology company’s stock worth $334,000 after acquiring an additional 360 shares during the period. Hedge funds and other institutional investors own 82.50% of the company’s stock.
In related news, VP Howard Benjamin sold 12,729 shares of the firm’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $35.34, for a total transaction of $449,842.86. Following the transaction, the vice president now directly owns 36,554 shares in the company, valued at $1,291,818.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 1.50% of the company’s stock.
RGEN has been the subject of a number of analyst reports. Zacks Investment Research upgraded Repligen from a “hold” rating to a “buy” rating and set a $43.00 price target for the company in a report on Thursday, October 5th. CL King initiated coverage on Repligen in a report on Monday, November 13th. They issued a “buy” rating and a $41.00 price target for the company. BidaskClub upgraded Repligen from a “hold” rating to a “buy” rating in a report on Saturday. Citigroup initiated coverage on Repligen in a report on Friday, December 8th. They issued a “buy” rating and a $45.00 price target for the company. Finally, TheStreet cut Repligen from a “b-” rating to a “c” rating in a report on Monday, November 13th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Repligen currently has a consensus rating of “Buy” and a consensus target price of $44.38.
Repligen Co. (RGEN) traded up $0.78 during trading on Tuesday, hitting $37.06. The stock had a trading volume of 239,118 shares, compared to its average volume of 238,250. The stock has a market cap of $1,580.55, a PE ratio of 62.81, a P/E/G ratio of 2.36 and a beta of 1.04. Repligen Co. has a 12 month low of $28.48 and a 12 month high of $46.81.
Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, November 9th. The biotechnology company reported $0.15 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.11 by $0.04. The company had revenue of $36.58 million during the quarter, compared to analysts’ expectations of $35.69 million. Repligen had a return on equity of 7.57% and a net margin of 16.93%. The business’s revenue was up 48.2% on a year-over-year basis. During the same period in the prior year, the business posted $0.08 EPS. equities analysts forecast that Repligen Co. will post 0.61 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Perceptive Advisors LLC Invests $3.35 Million in Repligen Co. (NASDAQ:RGEN) Stock” was first posted by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.truebluetribune.com/2018/01/03/perceptive-advisors-llc-invests-3-35-million-in-repligen-co-rgen.html.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.